Language
Country/Area
No result found
Why is Troxipide known as the guardian of the gastric mucosa? Uncover the secret of its protective mechanism!
Troxipide is gaining increasing attention in the treatment of digestive diseases because of its ability to effectively treat gastroesophageal reflux disease, gastric ulcers, and chronic and acute gastritis. This is widely used in markets in many countries such as Japan, China, South Korea and India. Troxipide is known as a "systemic non-antisecretory gastric mucosal protector", and its unique mechanism makes it a guardian of the gastric mucosa.
The mechanism of action of Troxipide
The protective effect of Troxipide is not affected by the pH value of the gastric contents, and its working principle can be divided into several main aspects:
Troxipide strengthens the gastric mucosal barrier by increasing the content of amino sugars, mucopolysaccharides and collagen in the gastric mucosa.
Protection of gastric mucosa
The gastric mucosa is composed of many components, including salt and other permeable components, free proteins, carbohydrate-rich glycoproteins, and water. Troxipide can strengthen the protection of gastric mucosa and promote the repair of gastric mucosa by increasing the content of amino sugars and mucopolysaccharides. Among them, amino sugars can stimulate the synthesis of glycoproteins, while mucopolysaccharides impart structural integrity to the gastric mucosa.
Stimulation of cytoprotective prostaglandins
With the introduction of Troxipide, the release of cytoprotective prostaglandins such as PGE2 is enhanced. These prostaglandins can stimulate the secretion of mucus, bicarbonate and phospholipids, enhance mucosal blood flow, thereby accelerating epithelial regeneration and mucosal healing.
Troxipide has been proven to increase the production of PG in gastric mucosal secretion, further promoting rapid epithelial repair.
Suppress gastric inflammation
Gastric inflammation is a complex biochemical reaction. Troxipide restores normal gastric mucosa by inhibiting multiple pro-inflammatory mediators. Research shows that Troxipide can help treat gastric mucosal inflammation by combating pro-inflammatory mediators, such as recombinant interleukin-8 (IL-8), as well as factors that trigger oxidative stress.
Promote mucosal metabolism
The parietal cells in the gastric wall are rich in mitochondria, which provide the energy needed to maintain the shape and function of the gastric mucosa. Troxipide can accelerate oxygen uptake in the marginal gastric mucosa, thereby improving tissue respiration and energy metabolism.
Stimulate mucosal microcirculation
Troxipide not only enhances mucosal blood flow and provides necessary nutrients and oxygen to the epithelium, but also removes and neutralizes toxic substances that diffuse from the lumen to the mucosa.
Anti-Helicobacter pylori effect
Troxipide also has the ability to inhibit enzymes released by Helicobacter pylori, which may cause damage to the host and trigger an inflammatory response.
Clinical experience
The efficacy of Troxipide in the treatment of gastric ulcers has been well established, with an overall response rate of 79.4%. In patients with duodenal ulcers, Troxipide demonstrated endoscopic healing rates of 53.3% and 73% at 8 and 12 weeks, respectively. The study also demonstrated the effectiveness of Troxipide in patients with acute gastritis, achieving an overall improvement rate of 82.9%.
Troxipide's safety and tolerability profile across multiple studies make it an ideal treatment option.
Safety and Tolerability
Based on an aftermarket study of more than 12,000 patients, only 0.75% of patients experienced drug-related side effects, and these side effects were generally mild. Compared with other drugs such as Ranidine, Troxipide's tolerability has been rated higher, with surveys showing that 93.67% of patients receiving Troxipide showed good tolerability.
Conclusion
Troxipide’s multiple protective mechanisms allow it to play an important role in the protection of gastric mucosa and is widely used in the treatment of a variety of digestive diseases. Whether future research can further reveal its potential in other gastrointestinal diseases will be a continued focus of the medical community?
